PERCEPTIVE ADVISORS LLC Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001224962
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q2 2026 · 107 positions · Total reported value $6.30B · Top-10 concentration 47.5% · Updated 2026-10-24
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
Turnover: 55.5% · 26 new · 28 cut · 12 exited
Active Share (vs S&P 500): 98.8% · vs QQQ: 99.7% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q1 2026 → Q2 2026): +23.3% · vs SPY +8.4% · Prev Value $4.76B — last quarter positions weighted by this quarter price moves · ranking
In its Q2 2026 13F filing, PERCEPTIVE ADVISORS LLC disclosed 107 equity positions with a combined reported value of $6.30B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 47.5% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.
The largest disclosed positions as of Q2 2026 were PRAX ($681.63M), SYRE ($383.48M), ASND ($310.39M). By sector, the heaviest allocations are Health Care 89.0%, Industrials 1.2%. Versus the prior quarter, allocation shifted toward Health Care (+1.4pp) and away from Other (-1.7pp).
Versus the prior quarter, PERCEPTIVE ADVISORS LLC opened 26 new positions, trimmed 28 and fully exited 12, a turnover rate of 55.5% of positions. The portfolio's overlap with the prior quarter was 68% of names.
The largest new positions opened in Q2 2026 were KARD ($195.59M), AVLN ($88.07M), BIIB ($59.67M).
Of the 12 positions fully exited versus the prior quarter, the largest were CNTA ($208.88M), DAWN ($37.64M), DRUG ($27.55M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q2 2026)
Fully Exited (vs previous quarter)
- CNTA CENTESSA PHARMACEUTICALS PLC · prev qtr: $208.88M
- DAWN DAY ONE BIOPHARMACEUTICALS I · prev qtr: $37.64M
- DRUG BRIGHT MINDS BIOSCIENCES INC · prev qtr: $27.55M
- BLTE BELITE BIO INC · prev qtr: $24.23M
- EVMN EVOMMUNE INC · prev qtr: $10.31M
- NMRA NEUMORA THERAPEUTICS INC. · prev qtr: $9.95M
- NBIX NEUROCRINE BIOSCIENCES INC · prev qtr: $8.57M
- IRD OPUS GENETICS INC · prev qtr: $8.35M
Insider Transactions (Form 4)
Latest PERCEPTIVE ADVISORS LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
| Transaction date | Activity | Security | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-10-26 | Opt exercise | LeonaBio, Inc. | 776,648 | $0.00 | SEC filing |
| 2026-08-26 | Buy | Immatics N.V. | 863,060 | $8.69 | SEC filing |
| 2026-07-20 | Award | Freenome, Inc. | 5,500,000 | $10.00 | SEC filing |
| 2026-06-17 | Award | Kardigan, Inc. | 20,706 | — | SEC filing |
| 2026-04-17 | Award | MeiraGTx Holdings plc | 555,555 | $9.00 | SEC filing |
Fund Profile
Perceptive Advisors is an SEC-registered 13F filer based in New York, NY, United States. As of Q2 2026 it reported 107 US equity positions with a combined value of $6.30B. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).
Firm Snapshot
- Headquarters: NEW YORK, NY, United States
- SEC registration: 801-71841 (status: Approved), registered 2010-10-04
- Regulatory AUM (Form ADV): $11.77B as of 2026-07-13
- Client mix (by RAUM): pension and profit-sharing plans 100%
- Manages 17 private funds, of which 6 hedge funds
Portfolio Structure
- 107 positions · $6.30B reported value (Q2 2026)
- Top 10 holdings = 47.5% of reported value
- Largest position: PRAX (PRAXIS PRECISION MEDICINES I) at 10.8%
- Average position size: $58.91M
Sector Tilt
- Health Care 89.0%
- Industrials 1.2%
- Financials 0.1%
- (classified holdings cover 90% of value)
Quarterly Activity
- Q2 2026: 26 new, 28 added, 28 reduced, 12 exited
- 25 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
2.04M | $681.63M | 10.81% | Hold | |
| 2 |
|
4.32M | $383.48M | 6.08% | Add | |
| 3 |
|
1.16M | $310.39M | 4.92% | Reduce | |
| 4 |
|
2.59M | $287.16M | 4.56% | Add | |
| 5 |
|
8.09M | $286.14M | 4.54% | Reduce | |
| 6 |
|
14.11M | $263.93M | 4.19% | Add | |
| 7 |
|
3.75M | $213.18M | 3.38% | Reduce | |
| 8 |
|
8.20M | $195.59M | 3.10% | New | |
| 9 |
|
1.58M | $195.19M | 3.10% | Hold | |
| 10 |
|
4.37M | $177.71M | 2.82% | Reduce | |
| 11 |
|
1.31M | $173.63M | 2.75% | Reduce | |
| 12 |
|
8.33M | $149.69M | 2.38% | Add | |
| 13 |
|
10.79M | $145.73M | 2.31% | Add | |
| 14 |
|
1.35M | $128.01M | 2.03% | Reduce | |
| 15 |
|
1.30M | $122.96M | 1.95% | Reduce | |
| 16 |
|
981.88K | $120.36M | 1.91% | Reduce | |
| 17 |
|
11.91M | $118.95M | 1.89% | Hold | |
| 18 |
|
4.18M | $109.34M | 1.74% | Add | |
| 19 |
|
3.38M | $105.57M | 1.68% | Add | |
| 20 |
|
10.38M | $105.18M | 1.67% | Hold | |
| 21 |
|
4.32M | $104.81M | 1.66% | Add | |
| 22 |
|
10.31M | $103.09M | 1.64% | Add | |
| 23 |
|
527.60K | $98.81M | 1.57% | Add | |
| 24 |
|
2.68M | $88.07M | 1.40% | New | |
| 25 |
|
1.00M | $70.03M | 1.11% | Hold | |
| 26 |
|
2.69M | $59.73M | 0.95% | Reduce | |
| 27 |
|
276.17K | $59.67M | 0.95% | New | |
| 28 |
|
1.36M | $52.30M | 0.83% | Reduce | |
| 29 |
|
116.81K | $48.55M | 0.77% | New | |
| 30 |
|
300.00K | $47.48M | 0.75% | New | |
| 31 |
|
566.00K | $44.88M | 0.71% | Add | |
| 32 |
|
1.30M | $43.32M | 0.69% | Add | |
| 33 |
|
1.61M | $42.49M | 0.67% | Reduce | |
| 34 |
|
170.00K | $40.96M | 0.65% | Hold | |
| 35 |
|
2.67M | $39.85M | 0.63% | Add | |
| 36 |
|
905.00K | $39.81M | 0.63% | Add | |
| 37 |
|
10.44M | $39.15M | 0.62% | Add | |
| 38 |
|
1.74M | $39.04M | 0.62% | Add | |
| 39 |
|
7.93M | $37.05M | 0.59% | Add | |
| 40 |
|
398.38K | $34.64M | 0.55% | Add | |
| 41 |
|
248.21K | $33.87M | 0.54% | Reduce | |
| 42 |
|
3.43M | $33.74M | 0.54% | Hold | |
| 43 |
|
773.34K | $32.23M | 0.51% | Add | |
| 44 |
|
1.22M | $31.81M | 0.51% | Hold | |
| 45 |
|
140.00K | $31.75M | 0.50% | New | |
| 46 |
|
118.45K | $28.99M | 0.46% | Reduce | |
| 47 |
|
2.00M | $28.60M | 0.45% | New | |
| 48 |
|
1.65M | $27.11M | 0.43% | Add | |
| 49 |
|
223.77K | $26.62M | 0.42% | Add | |
| 50 |
|
1.22M | $26.11M | 0.41% | Add | |
FAQ
What did PERCEPTIVE ADVISORS LLC buy in 2026-Q2?
In its 2026-Q2 13F filing, PERCEPTIVE ADVISORS LLC reported 107 equity positions worth $6.30B in aggregate; its largest disclosed positions were PRAX ($681.63M), SYRE ($383.48M), ASND ($310.39M).
How large is PERCEPTIVE ADVISORS LLC's portfolio?
PERCEPTIVE ADVISORS LLC reported $6.30B of long equity holdings across 107 positions as of 2026-Q2. Top-10 holdings account for 47.5% of reported value.
What is PERCEPTIVE ADVISORS LLC's investment style?
HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.